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Background: Reverse remodeling (RR) after cardiac resynchronization therapy (CRT) is associated with
favorable clinical outcomes in heart failure (HF). The renin-angiotensin-aldosterone system (RAAS) is in-
volved in the remodeling process.
Methods and Results: We assessed the association between RR and 8 common RAAS gene variants,
which were determined by TaqMan assays, in 156 outpatients with chronic HF. RR was defined as
aO15% decrease in left ventricular end systolic volume (LVESV) at 9 (interquartile range 7e12) months
after CRT. We matched 76 patients who did not show RR (RR) to 80 RRþ control subjects by age, sex,
HF etiology, New York Heart Association (NYHA) functional class and left ventricular ejection fraction
(LVEF). The frequency of the minor allele of the NR3C2 gene (rs5522 C/T), encoding the mineralocor-
ticoid receptor, was higher in RR than in RR (24/126 vs 10/150; P value after false discovery rate cor-
rection: !.0193). Conversely, LVESV decreased significantly less after CRT in carriers of the NR3C2
minor C allele (P 5 .02). After adjustment for age, sex, NYHA functional class, previous myocardial
infarction, atrial fibrillation, and LVEF, RR remained independently associated with NR3C2 C allele
carriage (odds ratio 3.093, 95% confidence interval 1.253e7.632).
Conclusions: The association of RR after CRT with a common polymorphism in the mineralocorticoid
receptor gene involved in aldosterone signaling suggests a possible role for variants in RAAS genes in
progressive LV function decline, despite apparently effective CRT. (J Cardiac Fail 2012;18:762e768)
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ticoid receptor.Reverse remodeling (RR) of dilated failing ventricles is
a generally accepted goal in the treatment of heart failure
(HF). RR can be obtained by medical therapy, as demon-
strated by the landmark randomized controlled trials of
renin-angiotensin-aldosterone system (RAAS) inhibitors
and beta-blockers. More recently, cardiac resynchronization
therapy (CRT) has also been shown to trigger RR in
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762on optimal medical treatment. Besides improving clinical
symptoms, quality of life, exercise tolerance, and survival
in patients with advanced HF,1,2 CRT reverses the remodel-
ing process by reducing ventricular size, mass, and mitral
regurgitation in both short and long terms.3e5
RR, as defined by decreases in left ventricular end-systolic
volume (LVESV) compared with preprocedural values, peaks
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with better clinical outcomes.3,6e8 Failure of RR after CRT is
therefore an important clinical issue with relevant prognostic
implications. Demographic, clinical, and procedural variables
have been associated with RR after CRT,9e15 but no data are
available currently on the possible association of genetic var-
iants with an RR phenotype.
The RAAS plays a major role in the pathophysiology of
HF, through increased vasoconstriction, sodium and water
retention, myocardial fibrosis, and ventricular remodeling,
and is a generally accepted therapeutic target in HF. Using
the candidate gene approach, genetic variance in the RAAS
has been previously associated with left-ventricular hyper-
trophy, remodeling or HF (susceptibility genes), or other
specific phenotypic expressions (modifier genes).16,17
We assessed, using a multicenter case-control design, the
prevalence of genetic variants in 6 RAAS genes that play
pivotal roles in cardiovascular function or signal transduc-
tion and that most likely affect the RR process in patients
with chronic systolic HF and different degrees of reverse
left ventricular (LV) remodeling after CRT.
Methods
Study Population
Out of a total population of 1,421 patients implanted with CRT
since 2002 at the 3 participating institutions, we enrolled 160 con-
senting subject who had undergone CRT $12 months earlier and
were consecutively reviewed in the electrophysiology outpatient
clinics of the 3 participating institutions from March to December
2009. CRT had been performed in all according to current guide-
lines,18 ie, advanced heart failure (New York Heart Association
[NYHA] functional class IIeIV), wide QRS complex ($120 ms),
depressed LV function (ejection fraction [LVEF] #35%), and LV
end-diastolic diameter O55 mm at baseline, through transvenous
implantation of a right ventricular defibrillation lead, an atrial
pacing lead (except for patients in atrial fibrillation), and a coronary
sinus lead for LVpacing. Entry criteria also included stable position-
ing of the left lead at the lateral or posterolateral wall level and
ventricular volumes measured at follow-up echocardiography
6e12 months after CRT. Patients with procedural failure, particu-
larly a nonfunctioning LV lead, were excluded.
Lack of reverse remodeling (RR) was defined as any change
in LVESV at follow-up echocardiography, 6e12 months after
CRT O15% compared with baseline values. For each RR
patient, a control subject with LVESV decrease O15% (RRþ)
matched by sex, NYHA functional class, HF etiology, age (within
10 years), and baseline LVEF (within 5%) was enrolled.
Blood was sampled for genetic analysis during a follow-up outpa-
tient visit. Timing of data collectionwas baseline, ie, the last available
data beforeCRT, and follow-up, ie, 6e12months after the procedure.
The study was approved by the Institutional Ethics Committees
of the 3 participating centers. Patients expressed their written
informed consents to participate.
Genotyping
The selected common variants within 6 RAAS genes have been
replicatively associated with HF phenotypes16 and were considered
as markers and/or functional variants. For the ACE gene, we
included 3 variants, because linkage and association analysissuggested their combinations to be better predictors for
angiotensin-converting enzyme (ACE) protein levels than either
one alone.19We included only variants with previously reportedmi-
nor allele frequencies ofO10% in a European ancestry population.
Genomic DNA was extracted from 200 mL of patients’ EDTA
blood with the use of the QIAamp DNA Blood kit (Qiagen,
Hilden, Germany) according to the manufacturer’s instructions.
Genotyping was performed at the University Clinic of M€unster,
Germany, blinded to remodeling status, with the use of TaqMan
SNP Genotyping Assays. Assays were purchased from Applied
Biosystems (Life Technologies Corporation, Carlsbad, California,
USA) and were applied using the ABI7900 real-time polymerase
chain reaction (PCR) system. Real-time PCR was performed in
a 384-well format with the use of 2.5 mL TaqMan Genotyping
Master Mix (2), 0.125 mL TaqMan SNP Genotyping Assay
(40), 2.375 mL DNase-free water, and 2 ng DNA. Real-time PCR
conditionswere as follows: initial denaturing at 95C for 10minutes,
40 cycles of 95C for 15 seconds, and 60C for 1 minute. Replicate
samples and samples without template were used as control.
From the original population of 160 subjects from whom blood
was sampled, successful genotyping was available for 156 patients.Echocardiographic Measurements
All patients underwent a comprehensive transthoracic echocar-
diographic examination at rest, with the use of conventional
methods using commercially available ultrasound machines equip-
ped with a 2.5e3.5-MHz phased-array sector scan probe, second
harmonic technology. LV volumes were measured and LVEF
obtained by 2- and 4-chamber view (Simpson’s rule). Intra- and
interoperator variabilities for volume measurements were 5% and
6%, respectively.Statistical Analysis
Data are expressed as median and interquartile range and
frequency (%). Chi-square test was used to compare categoric var-
iables, or the Fisher exact test if necessary, with Mantel-Haenszel
linear-by-linear association where appropriate. Student t test or
Mann-Whitney test was used to compare continuous variables.
The correlation between changes in LVESV and LVEF was inves-
tigated by Spearman correlation and presented by r and P values.
Concordance between RR criteria derived from LVESV or LVEF
changes was assessed by the k statistic.
Genotyping call rates were all O98%. Hardy-Weinberg equilib-
rium was tested by calculating the expected genotype frequencies
from the allele frequencies; deviation from the observed genotype
frequencies was determined by chi-square. Genotype distributions
in the 6 RAAS pathway genes analyzed were compatible with
Hardy-Weinberg equilibrium, except for rs1403543 polymorphism
in theAGTR2 (angiotensin receptor 2) gene, which was consequently
dropped fromfurther analysis, leaving5genes and7SNPs tobe tested
for association with RR (Table 1). Genetic association was tested by
comparing allelic frequencies between RR and RRþ groups. To
correct for multiple comparisons, we used the Benjamini and
Yekutieli false discovery rate method.20 Statistical significance was
declared at P # .0193 using the formula P 5 a/S(1/i), where
a5 .05 and i ranges from 1 to N, where N5 7 represents the number
of allele comparisons.
Group sample sizes of 76 RR and 80 RRþ achieve O80%
power to detect an allele frequency difference of 0.10 (odds ratio
[OR] 2.58) for an allele of 11% population frequency.
Table 1. Association of the Studied Polymorphisms with Cardiovascular Phenotypes
Gene SNP Major Allele Minor Allele Reported Association
AGT rs699 G A HF occurrence; LV hypertrophy; LV size
ACE rs4291 A T Hypertension
ACE rs4646994 Ins Del HF occurrence and phenotype; LV hypertrophy; LV size
ACE rs4343 A G Reduced risk of hypertension (A allele)
AGTR1 rs5186 A C HF phenotype; LV hypertrophy; LV size
CYP11B2 rs1799998 T C HF phenotype; LV hypertrophy; LV size
NR3C2 rs5522 T C Enhanced physiologic stress responses
ACE, angiotensin-converting enzyme; AGT, angiotensinogen; AGTR1, angiotensin receptor 1; CYP11B2, aldosterone synthase; HF, heart failure; LV, left
ventricular; NR3C2, mineralocorticoid receptor; SNP, single-nucleotide polymorphism.
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adjusted for clinically relevant potential confounders by multivari-
able logistic regression. Odds ratios with their corresponding 95%
confidence intervals (CIs) were estimated. Hosmer-Lemeshow
U-statistic was calculated as a measure of fit.
Two-sided P values of!.05 were considered to be statistically
significant. The Statistical Package for the Social Sciences (SPSS)
v17 was used for all analyses.Results
Characteristics of RR
Table 2 shows the preprocedural clinical characteristics of
the study population. LVESV changes were assessed at
follow-up 9 (7e12) months after CRT, compared with the
preprocedural echocardiogram. Eighty patients were classi-
fied as RRþ and 76 as RR. The 2 groupswerewell matched
by baseline clinical characteristics, except for prevalence of
diabetes (RR 24% vs RRþ 11%; P 5 .06).
After CRT, both LV volumes decreased and LVEF
improved significantly in RRþ, whereas they were un-
changed in RR (Fig. 1). As expected, changes from base-
line to follow-up in LVESV and LVEF were correlatedTable 2. Characteristics of the St
All (n 5 156)
Sex, male 136 (87%)
Ischemic etiology 79 (51%)
History of hypertension 43 (27%)
Diabetes 27 (17%)
Previous myocardial infarction 63 (41%)
Atrial fibrillation 25 (16%)
Anemia (Hb !11.5 g/dL) 11 (8.5%)
Kidney dysfunction (creatinine O2 mg/dL) 7 (5.5%)
NYHA functional class IIIeIV 111 (71%)
Beta-blockers 126 (82%)
RAAS inhibitors 145 (97%)
MR antagonists 97 (64%)
Age (y) 62 (5670)
Months since symptom onset 60 (24e96)
QRS duration (ms) 160 (140e180)
LVEF (%) 27 (22e30)
LVEDV (mL) 227 (190e310)
LVESV (mL) 170 (135e231)
Months to follow-up echo after CRT 9 (7e12)
LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fr
receptor; NYHA, New York Heart Association; RAAS, renin-angiotensin-aldost
Values are expressed as n (%) or median (interquartile range).(Spearman r coefficient5 0.72; P! .001). Concordance
between the 15% decrease LVESV cutoff and improved
LVEF was moderate: k value was 0.56 (P ! .001) for an
absolute 5% LVEF increase and 0.43 (P ! .001) for
a 15% relative LVEF increase. At follow-up (Table 3), a sig-
nificantly greater proportion of RRþ than of RR subjects
improved by at least 1 NYHA functional class (75% vs
55%; P ! .01), whereas no differences were observed in
drug treatment between groups.RAAS Variants and RR
Allele frequencies of the 7 analyzed SNPs are shown in
Table 4. Only the minor (C) allele frequency of the NR3C2
gene, encoding the mineralocorticoid receptor (MR), was
significantly higher in RR than in RRþ. After CRT,
LVESV decreased significantly less in carriers of NR3C2
minor allele (P 5 .02; Fig. 2). Conversely, the NR3C2
minor C allele was associated with a graded lesser extent
of RR (P 5 .0008; Fig. 3).
MR antagonist treatment conditions did not differ be-
tween carriers of the minor allele and noncarriers: Admin-
istration rates were 67% vs 61% (P 5 .09), and daily dosesudy Population Before CRT
RR (n 5 76) RRþ (n 5 80) P Value
69 (91%) 67 (84%) .23
40 (53%) 39 (49%) .63
22 (31%) 21 (28%) .72
18 (24%) 9 (11%) .06
33 (44%) 30 (39%) .51
14 (18%) 11 (14%) .51
4 (6.3%) 7 (10.4%) .53
4 (6.3%) 3 (4.7%) 1.00
53 (70%) 58 (72%) .73
63 (83%) 63 (83%) 1.00
75 (99%) 70 (96%) .36
51 (67%) 46 (61%) .50
61 (56e70) 64 (57e71) .68
60 (24e114) 48 (24e80) .25
160 (140e180) 169 (150e188) .16
27 (23e30) 27 (22e30) .66
227 (174e295) 230 (200e330) .25
164 (121e222) 178 (140e240) .25
10 (7e12) 9 (7e12) .88
action; LVESV, left ventricular end-systolic volume; MR, mineralocorticoid
erone system; RR, reverse remodeling.
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Fig. 1. Left ventricular (LV) end-diastolic (LVEDV) and end-
systolic (LVESV) volume and ejection fraction (LVEF) at baseline
(open boxes) and follow-up (filled boxes) according to the prespe-
cified reverse remodeling phenotype. Between-group differences
at follow-up were significant for all measurements(P ! .001).
Box plots show median (line), interquartile range (box), and
extreme values (whiskers).
Table 3. Follow-Up Functional Class and Drug Treatment
According to Evidence of RR, n (%)
All
(n 5 156)
RR
(n 5 76)
RRþ
(n 5 80)
P
Value
NYHA functional class .01
Unchanged/increased 54 (35%) 34 (45%) 20 (25%)
Decreased $1 100 (65%) 41 (55%) 59 (75%)
Beta-blockers 136 (88%) 67 (88%) 69 (89%) 1.00
RAAS inhibitors 144 (97%) 73 (96%) 71 (97%) 1.00
MR antagonists 81 (53%) 43 (57%) 38 (48%) .34
Abbreviations as in Table 2.
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respectively.
By multivariable logistic regression, after adjustment for
age, sex, previous myocardial infarction, NYHA functional
class, atrial fibrillation, baseline LVEF, and diabetes, pres-
ence of theminor allele in theNR3C2gene remained indepen-
dently associated with lack of RR during follow-up (Table 5).
The model showed good calibration (Hosmer-Lemeshow
goodness of fit statistic: P 5 .95).Discussion
To the best of our knowledge, this is the first report on the
role of variants in candidate genes linked to cardiac struc-
ture and function in LV remodeling response after CRT.
The main finding of our study that excluded subjects with
procedural failure is the association between lack of RR
after CRT and the minor allele of the NR3C2 gene involved
in aldosterone signaling, even after adjustment for known
clinical confounders.
RR occurs in more than one-half of patients and peaks
between 6 and 12 months after CRT. Its prevalence varies
with the echocardiographic variable and cutoff chosen and
timing of assessment.6,7,21,22 We used LVESV decrease as
marker of RR because of its reported association with out-
comes, and selected the more stringent cutoff of 15%, rather
than the 10% criterion coupled to survival at 6 months,
because by definition all of our patients were alive at the
time of genetic characterization. Consistent with previous
findings,22 we observed only moderate agreement between
LVESV and LVEF remodeling cutoff values. However,
RRþ showed a significantly greater LVEF improvement
than RR (Fig. 1).
In our white population, which is representative of other
series of HF patients on optimized medical treatment un-
dergoing CRT, 51% of the subjects showed a LVESV
decrease of O15% at a median time of 9 months after
the procedure. The observed balance between RR and
RRþ in acknowledged key clinical predictors of outcome
dims their confounding effect and minimizes bias in the
evaluation of genetic variance. Factors underlying response
to CRT regarding RR are probably many, and among them
patients’ genetics may well have a role.23
RR patients had a higher prevalence of diabetes of bor-
derline significance. Several reports have focused on the
impact of diabetes on response to CRT.24,25 Intriguingly,
all of our diabetic patients carrying the minor allele of
the NR3C2 gene had an RR phenotype, but the associa-
tion was not confirmed after adjustment for clinical con-
founders, including previous myocardial infarction.
Because the scope of our investigation was restricted to
patients in whom technically successful CRT was not fol-
lowed by improved chamber size and pump function, we in-
vestigated RAAS genetic variants linked to altered protein
function and ventricular structure. In this population, only
Table 4. Allelic Frequencies of the Analyzed RAAS Gene Variants According to RR (n 5 Number of Successfully Tested Cases)
Gene SNP Alleles RR (n 5 76) RRþ (n 5 80) P Value* (Allele)
AGT rs699 (n 5 155) A/G 89/63 90/68 NS
ACE rs4291 (n 5 155) T/A 53/97 56/104 NS
ACE rs4646994 Ins/Del 65/87 63/97 NS
ACE rs4343 G/A 82/70 96/64 NS
AGTR1 rs5186 (n 5 155) C/A 49/103 43/115 NS
CYP11B2 rs1799998 (n 5 155) C/T 78/74 64/94 NS
NR3C2 rs5522 (n 5 155) C/T 24/126 10/150 !.0193
Del, deletion; Ins, insertion; other abbreviations as in Tables 1 and 2.
*Significance level after false discovery rate correction: !.0193.
766 Journal of Cardiac Failure Vol. 18 No. 10 October 2012the rs5522 polymorphism of the NR3C2 gene was signifi-
cantly associated with lack of RR, suggesting its possible
modifier effect on the putative mechanisms of structural
change.
The deleterious role of aldosterone and MR activation in
the heart has recently been extensively reviewed.26e29
Aldosterone induces hypertrophy and the dysregulation of
proliferation and apoptosis in the myocardium and vessel
wall, which lead to fibrosis and chamber remodeling. MR
activation, by changes in redox status or by aldosterone levels
inappropriate for sodium status, is accompanied by vascular
inflammation and end-organ damage. Deletion of MR in
cardiomyocytes ameliorates adverse remodeling after myo-
cardial infarction in the rodent model.30 In clinical trials in
both advanced and mild HF,31 MR antagonists at doses
devoid of relevant natriuretic effects improved mortality
and morbidity, despite plasma aldosterone levels in the low
to normal range. The adverse effects of MR stimulation
may in fact be independent from peripheral hormone concen-
trations. In the Framingham Offspring Study,32 there was no
association between plasma aldosterone levels and variants
in the MR and aldosterone synthase genes, with an estimated
heritability of serum aldosterone of 0.10. In the RALES
(Randomized Aldactone Evaluation Study) trial, 25 mgNR3C2 genotype
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LV
ES
V
 ch
an
ge
fr
om
ba
se
lin
e
%
45
30
15
0
-15
-30
-45
-60
-75
Fig. 2. Distribution of percentage changes in left ventricular end-
systolic volume (LVESV) according to NR3C2 minor (C) allele
carriage. Box plots show median (line), interquartile range
(box), and extreme values (whiskers).spironolactone had no apparent effect on sodium retention
score, urinary sodium excretion, or body weight but was
associated with reduced mortality and morbidity.
The negative effects of aldosterone on myocardial tissue
might be mediated by genetically modulated increased
activity of the MR receptor. The independent association
between NR3C2 minor allele and RR phenotype in the
present population suggests that this genetic variant might
result in MR up-regulation, heightened susceptibility even
to normal aldosterone levels, adverse changes in extracellu-
lar matrix, and a lower probability of favorable CRT effects.Study Limitations
The population studied in this pilot investigation, although
phenotypically well characterized and balanced across many
clinical confounders, was retrospectively enrolled, relatively
small, and possibly not adequately powered to detect even
small phenotypic differences for all genetic variants studied.
However, we used stringent phenotypic criteria for RR that
had previously been validated through hard end points of
morbidity and mortality6e8 and restricted our analysis to
genes with reported minor allele frequencies of O10% in
a population with European ancestry.> 0
n = 35
-15 to 0
n = 41
-29 to -15
n = 35
TT CT+CC
0%
10%
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30%
40%
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%
Fig. 3. Frequency percentage of NR3C2 minor (C) allele carriage
(black) according to different degrees of reverse remodeling as
defined by changes in left ventricular end-systolic volume
(DLVESV) at follow-up compared with baseline.
Table 5. Variables Associated with Lack of Reverse
Remodeling by Multivariable Logistic Regression
P
Value
Adjusted
Odds Ratio
95%
Confidence
Interval
Age .488 0.987 0.952e1.024
Male vs female sex .120 2.397 0.797e7.203
Previous myocardial infarction .873 1.061 0.512e2.201
Diabetes .055 2.579 0.981e6.781
Atrial fibrillation .317 1.641 0.622e4.331
NYHA class IIIeIV vs II .482 0.765 0.363e1.614
Left ventricular ejection fraction .858 1.006 0.945e1.070
NR3C2 minor (C) allele carriage
(CC-CT vs TT genotypes)
.014 3.093 1.253e7.632
Abbreviations as in Tables 1 and 2.
Reverse Remodeling and RAAS Genetic Variants  De Maria et al 767We did not assess plasma aldosterone levels or urinary
sodium excretion. However, the functional effects of the
polymorphism on plasma aldosterone levels may be particu-
larly difficult to elucidate inHFpatients on optimal drug ther-
apy. In severe HF, plasma aldosterone concentrations are
elevated and correlate with resistance to loop diuretics.
Even under effective pharmacologic RAAS blockade with
ACE inhibitors, aldosterone breakthrough occurs in a sub-
stantial proportion of HF patients with return to pretreatment
plasma hormone levels32 so large as to overcome possible
differences in gene products due to polymorphisms. On the
other hand, it is conceivable that biomarkers may exist that
differentially interact with genotypes on phenotype
expression.
Clinical Implications
The genetic findings of this pilot investigation are di-
rectly tied to the biology underlying the remodeling pro-
cess. Candidate genes of the RAAS have multiple lines
of evidence to support a possible role in a lack of RR:
the NR3C2 polymorphism is involved in aldosterone sig-
naling in the myocardium and vascular wall, and blockade
of the MR prevents progression of cardiac damage in the
experimental model and in human disease. Nonetheless,
our findings remain largely speculative unless they are
proved in larger series. In particular, the role of pharmaco-
genomic profiling to tailor levels of aldosterone blockade
requires careful investigation in adequately powered sam-
ples to account for different confounders and dosing. For
this purpose, well designed registries33 or biobanks from
randomized controlled trials may prove to be more
suitable.
Conclusion
Lack of RR after CRT was linked in the present series to
genetic variants involved in aldosterone signaling that have
been previously associated with cardiovascular phenotypes.
Whether genetic characterization might better identify HF
patients who may be most likely to benefit from device
implantation deserves further investigation.Acknowledgments
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